X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (38) 38
oncology (35) 35
egfr (33) 33
index medicus (31) 31
mutation (27) 27
gefitinib (25) 25
receptor, epidermal growth factor - genetics (25) 25
lung cancer (19) 19
lung neoplasms - genetics (19) 19
lung neoplasms - pathology (19) 19
lung neoplasms - drug therapy (18) 18
carcinoma, non-small-cell lung - genetics (17) 17
erlotinib (17) 17
lung cancer, non-small cell (17) 17
cell line, tumor (16) 16
female (16) 16
carcinoma, non-small-cell lung - drug therapy (15) 15
receptor, epidermal growth factor - antagonists & inhibitors (15) 15
carcinoma, non-small-cell lung - pathology (14) 14
quinazolines - pharmacology (14) 14
antineoplastic agents - pharmacology (13) 13
cell biology (12) 12
cell lung-cancer (12) 12
receptor, epidermal growth factor - metabolism (12) 12
acquired-resistance (11) 11
growth-factor-receptor (11) 11
male (11) 11
respiratory tract diseases (11) 11
tyrosine kinase inhibitors (11) 11
cancer (10) 10
egfr mutation (10) 10
egfr mutations (10) 10
genetic aspects (10) 10
aged (9) 9
animals (9) 9
drug resistance, neoplasm (9) 9
epidermal growth factor (9) 9
mutations (9) 9
protein kinase inhibitors - pharmacology (9) 9
chemotherapy (8) 8
growth-factor receptor (8) 8
lung neoplasms - metabolism (8) 8
middle aged (8) 8
non-small cell lung cancer (8) 8
nsclc (8) 8
resistance (8) 8
tumors (8) 8
tyrosine kinase inhibitor (8) 8
1st-line treatment (7) 7
adult (7) 7
analysis (7) 7
apoptosis (7) 7
phosphorylation (7) 7
quinazolines - therapeutic use (7) 7
sensitivity (7) 7
targeted therapy (7) 7
tyrosine kinase (7) 7
antineoplastic agents - therapeutic use (6) 6
blotting, western (6) 6
carcinoma, non-small-cell lung - enzymology (6) 6
cell survival - drug effects (6) 6
drug resistance (6) 6
epidermal growth factor receptor (6) 6
expression (6) 6
gene-mutations (6) 6
health aspects (6) 6
open-label (6) 6
pathology (6) 6
respiratory system (6) 6
therapy (6) 6
activating mutations (5) 5
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - genetics (5) 5
afatinib (5) 5
carcinoma, non-small-cell lung - metabolism (5) 5
care and treatment (5) 5
drug-resistance (5) 5
epidermal-growth-factor (5) 5
erlotinib hydrochloride (5) 5
exons - genetics (5) 5
inhibitors (5) 5
kinases (5) 5
lung neoplasms - enzymology (5) 5
mutation - genetics (5) 5
pharmacology & pharmacy (5) 5
prognosis (5) 5
protein kinase inhibitors - therapeutic use (5) 5
research paper (5) 5
tyrosine (5) 5
adenocarcinoma (4) 4
aged, 80 and over (4) 4
apoptosis - drug effects (4) 4
biochemistry & molecular biology (4) 4
breast-cancer (4) 4
combination (4) 4
gene mutations (4) 4
growth (4) 4
hematology, oncology and palliative medicine (4) 4
inhibitor (4) 4
kinase inhibitors (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 6/2015, Volume 75, Issue 6, pp. 1229 - 1236
Journal Article
Journal Article
Journal Article
Lung Cancer, ISSN 0169-5002, 2011, Volume 74, Issue 1, pp. 35 - 40
Abstract Background Recently, we have reported that EGFR mutation-specific antibodies performed well in immunohistochemical analysis, with good sensitivity. We... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Non-small-cell lung cancer | Activating EGFR mutations | Immunocytochemistry | Effusion cytology | Mutation-specific antibody | ANTIBODIES | DIAGNOSIS | GEFITINIB | ADENOCARCINOMA | TREATED PATIENTS | P53 | ONCOLOGY | RESPIRATORY SYSTEM | EPIDERMAL-GROWTH-FACTOR | Receptor, Epidermal Growth Factor - genetics | Recurrence | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung Neoplasms - physiopathology | Carcinoma, Non-Small-Cell Lung - physiopathology | Polymerase Chain Reaction - methods | Receptor, Epidermal Growth Factor - metabolism | DNA - cerebrospinal fluid | DNA - analysis | Sensitivity and Specificity | Pleural Effusion, Malignant | Adult | Female | Biomarkers, Pharmacological - cerebrospinal fluid | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - immunology | Biomarkers, Pharmacological - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Exons - genetics | Lung Neoplasms - therapy | Immunohistochemistry - methods | Carcinoma, Non-Small-Cell Lung - therapy | Quinazolines - therapeutic use | Aged | Lung Neoplasms - diagnosis | Sequence Deletion - genetics | Viral antibodies | Medical colleges | Peptides | Analysis | Antibodies | Genetic aspects | Nucleic acids | Lung cancer, Non-small cell
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 12/2014, Volume 455, Issue 3-4, pp. 269 - 276
Journal Article
Lung Cancer, ISSN 0169-5002, 2011, Volume 75, Issue 2, pp. 161 - 166
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 45, pp. 73618 - 73637
Triple-negative breast cancer (TNBC) is characterized by overexpression of epidermal growth factor receptor (EGFR) and activation of its downstream signaling... 
Cytotoxicity | Epidermal growth factor receptor | Cell cycle | Anti-EGFR targeted therapy | Triple-negative breast cancer | 1ST-LINE TREATMENT | triple-negative breast cancer | cell cycle | epidermal growth factor receptor | anti-EGFR targeted therapy | BRCA1 MUTATIONS | DRUG-RESISTANCE | METASTATIC COLORECTAL-CANCER | CELL BIOLOGY | CELL LUNG-CANCER | GROWTH-FACTOR RECEPTOR | TARGETED THERAPIES | RANDOMIZED PHASE-II | CETUXIMAB PLUS IRINOTECAN | GENE COPY NUMBER | cytotoxicity | Phosphorylation | Apoptosis - drug effects | Humans | Cyclins - genetics | ras Proteins - metabolism | Molecular Targeted Therapy | Triple Negative Breast Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - metabolism | Triple Negative Breast Neoplasms - pathology | Inhibitory Concentration 50 | Female | Gene Expression Regulation, Neoplastic - drug effects | Cell Survival - drug effects | Antibodies, Monoclonal - pharmacology | Protein Kinase Inhibitors - administration & dosage | Triple Negative Breast Neoplasms - genetics | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - metabolism | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | G1 Phase Cell Cycle Checkpoints - drug effects | Mitogen-Activated Protein Kinases - metabolism | Life Sciences | Biomolecules | Molecular biology | Biochemistry, Molecular Biology | Genomics | Cancer
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 3/2005, Volume 102, Issue 10, pp. 3788 - 3793
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 03/2012, Volume 13, Issue 2, pp. 107 - 114
Advanced nonsmall-cell lung cancer (NSCLC) harboring activating mutations of epidermal growth factor receptor (EGFR) are particularly sensitive to tyrosine... 
Erlotinib | Nonsmall-cell lung cancer | Mutation | Gefitinib | EGFR
Journal Article
Lung Cancer, ISSN 0169-5002, 06/2018, Volume 120, pp. 70 - 74
Although epidermal growth factor receptor ( ) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene ( ) mutations were thought to be mutually exclusive in patients... 
KRAS | NGS | NSCLC | Erlotinib | EGFR | ONCOLOGY | RESPIRATORY SYSTEM | AFATINIB | CANCER | Tyrosine | Medical colleges | Epidermal growth factor | Sarcoma | Analysis | Genetic research | Genetic aspects | Lung cancer, Non-small cell
Journal Article